Tag: Insulin pump
PharmaSens adds two to board
November 6, 2024HME News Staff
BIEL/BIENNE, Switzerland – PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors. The Swiss company is developing an insulin delivery platform and is working to bring to patients the first all-in-one wearable patch device integrating both insulin delivery and continuous glucose sensing. "Welcoming Dr. Bob Gabbay and James Peterson to our board is a great honor and represents...
Tandem offers update on recall
August 21, 2024HME News Staff
SAN DIEGO – Tandem Diabetes Care on Aug. 9 emailed notices to customers impacted by a recall of its Apple OS t:connect mobile app. The recall, issued in March, relates to an issue that can cause rapid depletion of a user’s t:slim X2 insulin pump battery, causing the insulin pump to shut down sooner than expected. Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release. Tandem strongly...
Tandem integrates with Dexcom
May 29, 2024HME News Staff
SAN DIEGO – The Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 continuous glucose monitoring systems (CGMs). Tandem Mobi, an automated delivery system (AID), launched in the United States earlier this year. “Choice is a hallmark of our offerings, and we’ve proven this commitment with the expansion of our insulin pump portfolio and extended CGM compatibilities,” said John Sheridan, president and CEO of Tandem...
Insulet’s Omnipod fuels growth
February 23, 2024HME News Staff
ACTON, Mass. – Insulet reported full year 2023 revenues $1.7 billion, up 30% compared to 2022. Fourth quarter 2023 revenue was $509.8 million, up nearly 38%. Total Omnipod revenue was $501 million; of that, US Omnipod revenue was $394.6 million, an increase of nearly 43%. “2023 was another transformational year for Insulet,” said Jim Hollingshead, president & CEO. “The rapid adoption of Omnipod 5 helped fuel our eighth consecutive year of more than 20% constant currency revenue...
Tandem Mobi gets FDA approval
July 13, 2023HME News Staff
SAN DIEGO – Tandem Diabetes Care has received U.S. Food and Drug Administration clearance for the Tandem Mobi insulin pump for people with diabetes age 6 and up. The Tandem Mobi is fully controllable from a mobile app. “Testing the limits of pump miniaturization, Tandem Mobi joins the t:slim X2 pump in our family of insulin delivery solutions bringing new options in wearability, the flexibility to disconnect, and full phone control,” said John Sheridan, president and CEO. “Through...
Tandem study shows benefits of its insulin pump tech in kids
March 20, 2023HME News Staff
SAN DIEGO – Tandem Diabetes has published results from the pediatric artificial pancreas (PEDAP) clinical trial in the New England Journal of Medicine showing an increase of about three hours per day time in range in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology compared to those on a standard insulin pump or multiple daily injections. “The safety and efficacy outcomes observed in this study support using Control-IQ...
CMS details process for new insulin cap
February 20, 2023HME News Staff
WASHINGTON – Part B co-insurance for a month’s supply of insulin used in an insulin pump covered under the DME benefit can’t exceed $35 starting on July 1, 2023, according to an MLN facet sheet. CMS will adjust payments to suppliers and pharmacies to account for the balance of the reduced co-insurance. Suppliers will continue to get the Medicare payment amount for the insulin (average sales price plus 6%), minus any applicable co-insurance, which, again, is now capped at $35. “Don’t...
Tandem backs use of insulin pump
November 15, 2022HME News Staff
SAN DIEGO – Tandem Diabetes Care has announced the results from a prospective, multi-center, single-arm study of adults living with Type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology. Data from the study, which was presented at the 22nd Annual Diabetes Technology Meeting, demonstrated the system to be safe during six weeks of use, with a substantial improvement in time in range and mean glucose related to...
Diabetes in the news, in my life
February 2, 2017Theresa Flaherty, Managing Editor
CGMs are all around me. Ads for the Dexcom G5, in particular, keep popping up on websites. I am guessing this is because I Googled it while writing a story about Medicare's recent decision to start paying for certain CGMs (the Dexcom currently being the only one that meets the criteria at this time).
I also met with a new CDE at the diabetes center this week. “Have you ever considered getting an insulin pump?” asked Sarah the CDE.
(Syringes are so 1980s.)
I get asked this every year or...